cyrilzakka/clinical-trials huggingface dataset:
Brain Mechanisms of Human Motivation

This study aims to investigate reward learning across the mood disorder spectrum and to investigate the predictive validity of reward learning for subsequent symptom severity.

The study involves five sessions. In the first session, participants will play a computer task. In the second session, participants will go through a clinical interview and will have an EEG recording while playing another computer task. In the third session, participants will undergo an fMRI scan while playing another computer task. All tasks assess reward learning. At three and six months after the final session, participants will come back for a follow-up interview session during which a clinician will assess symptom severity. There will be no intervention in this study.

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Right-handed
* (For mood disorder group only) Stable medication over the past 8 weeks OR absence of any psychotropic medications for at least 2 weeks (for follow-up analyses testing effects in medication-free patients):

  * 6 weeks for fluoxetine,
  * 6 months for neuroleptics,
  * 2 weeks for benzodiazepines,
  * 2 weeks for any other antidepressants
  * 4 weeks for any mood-stabilizers

Exclusion Criteria:

* Suicidal ideation where outpatient treatment is determined unsafe by the study clinician
* Pregnant women or women of childbearing potential who 1) have not completed a negative urine pregnancy test prior to the MRI scan and/or 2) are seeking to become pregnant or believe that they may be pregnant
* Serious/unstable medical illness (e.g., cardiovascular, renal, endocrine, neurologic disease)
* Clinical or laboratory evidence of hypothyroidism
* History of seizure disorder, history or current diagnosis of dementia, score \< 26 on the MMSE at screening
* History or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS, patients with mood congruent or mood incongruent psychotic features, anorexia nervosa, obsessive compulsive disorder
* Lifetime history of stimulant dependence (e.g., cocaine, amphetamines)
* Current use of Methylphenidate (Ritalin) and other ADHD medications with dopaminergic effects
* Patients with a lifetime history of electroconvulsive therapy (ECT)
* Failure to meet standard MRI safety requirements
The Effect of Kangaroo Care on Parents' Perceived Parenting Self-Efficacy, Infant Attachment and Newborn Vital Signs

This study was planned to determine the effect of kangaroo care applied by parents of premature newborns in the neonatal intensive care unit on the newborn's vital signs, perceived parenting self-efficacy level and attachment to the baby.

The research is a randomized controlled trial and an experimental research design will be used. The research will be carried out with two groups as experimental (newborns given kangaroo care by both mother and father) and control (newborns given kangaroo care only by the mother) groups.

Eligibility Criteria:
Inclusion Criteria:

* Parents who volunteered to participate in the research
* Parents who are Turkish citizens and speak Turkish
* Preterm baby born between 28-37 weeks staying in the neonatal intensive care unit
* The mother and father do not have any obstacles in taking care of the kangaroo.
* Mothers and fathers who can come to the hospital regularly on the specified days will be included in the study.

Exclusion Criteria:

* Not volunteering to participate in the research
* Parent's inability to speak Turkish
* Presence of a life-threatening major malformation or serious perinatal complication in the premature baby
* Babies with umbilical catheters and central venous catheters will not be included in the study.
Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development

This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3, 5 and 10-12 year after delivery.

The purpose of this phase 1 is to :

* assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes;
* assess levels of maternal adipokines as determinants of development and fetal growth;
* determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns.

The purpose of this phase 2 is to:

* identify DNA methylation variations at birth that are predictive of childhood overweight/obesity.
* identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity.
* establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age).
* identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3, 5 and 10 years of age.


Eligibility Criteria:
Inclusion Criteria:

* age ≥ 18 yrs
* gestational age between 6 and 13 weeks from last menstrual period
* no recognized diabetes or drugs interfering with glucose metabolism
* alcohol \< 2 drinks/day
* not involved in regular high intensity physical activity
* otherwise good health status

Exclusion Criteria:

* twin pregnancy
Establishing Standards for Normal Pancreatic EUS

There is tremendous variability in regard to provider perception of findings on EUS for chronic pancreatitis. This study performs tandem EUS exams between expert endosonogrpahers to determine the validity of minimal standard criteria.

Chronic pancreatitis is a very challenging disease to diagnose as their is no gold standard for diagnosis. Increasingly, endoscopic ultrasound (EUS) has been used as a means of diagnosing chronic pancreatitis. However, there are questions about whether intra-rater reliability and/or validity are high enough to warrant using EUS to make the diagnosis of chronic pancreatitis.

The purpose of this observational study is to determine the degree of correlation between two expert endosonographers in evaluating minimal standard criteria (MST) in the same patient during the same EUS exam. Patients both with and without chronic pancreatitis will be included in the study to try and determine the validity and reliability of back-to-back EUS examinations.

Eligibility Criteria:
Inclusion Criteria:

* Undergoing upper EUS for evaluation of the pancreas

Exclusion Criteria:

* pregnancy
* age less than 18
* inability to provide written informed consent
Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

The purpose of this study is to examine the safety and tolerability after administration of trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults.

This is a double-blind and randomized study in healthy adults. The duration of study will be approximately 90 days per participant. The study will include 4 visits: Day 1 (for vaccination), Day 4, Day 22 and day 90 (Follow-up visits). Safety and tolerability will be assessed by the rate of solicited, unsolicited, and serious adverse events.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male or female adults
* Body Mass Index \<= 30 kilogram per square meter (kg/m\^2)
* Written informed consent

Exclusion Criteria:

* Vaccination with 2013/2014-seasonal influenza vaccine and/or receipt of any vaccine in the 4 weeks preceding receipt of study vaccine and/or any vaccination planned within 3 weeks from the study vaccine
* Diagnosis (by rapid test, performed at clinic/hospital laboratory) of laboratory-confirmed influenza in the 2013/2014 season
* Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease
* Acute febrile illness (greater than or equal to 38.0 celcius)
* Pregnancy as assessed by urine pregnancy test before vaccination, or lactation. Women of childbearing potential (that is, not surgically sterilized/hysterectomized or post-menopausal for more than 2 years) will be excluded if one of the following criteria is met: 1). Intention to become pregnant during the course of the study or to donate eggs (ova, oocytes) for the purposes of assisted reproduction 2). If heterosexually active, not using or not willing to continue using a medically reliable method of contraception for the entire study duration (up to 90 days). A medically reliable method of contraception includes oral contraceptive preparation (for example pills), hormonal implant, progestative injection, patch contraceptive formulation, an intrauterine device, concomitant use of barrier method and spermicide, or another method considered sufficiently reliable by the investigator in individual cases
Outcomes Post Treatment: Impact on Motor Impairment of Sleep Efficiency in SCI (OPTIMISE SCI Trial)

This randomized clinical trial will compare three groups of individuals with cervical/thoracic, complete or incomplete spinal cord injury (SCI) that will undergo: (i) early CPAP therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs) among adults at 6 weeks after SCI; (ii) delayed CPAP therapy in the management of moderate-to-severe SRBDs among adults at 22 weeks after SCI; and (iii) no treatment as they either have mild or no SRBD.


Eligibility Criteria:
Inclusion Criteria:

* English-speaking adults (18 years of age or older)
* Acute (≤ 30 days after injury), cervical/thoracic (injury level at C2 to T12), complete or incomplete (AIS A to D) SCI
* Not being treated for sleep apnea prior to the spinal cord impairment onset.

Exclusion Criteria:

* Non-traumatic spinal cord disease at risk for neurologic progression (e.g., demyelinating spine diseases such as neuromyelitis optica and multiple sclerosis, spinal cord malignancy)
* Concomitant diseases of the central nervous system
* Preinjury chronic pain
* Other pre-existing diseases of the central nervous system
* Significant psychiatric disorders with recent episode of exacerbation
* Neuromuscular diseases
* Current substance misuse
* Known history of primary hypersomnia or secondary hypersomnia of any cause except for SRBDs (e.g., hypothyroidism, moderate or severe iron deficiency anemia, infections, depression, kidney failure, chronic fatigue syndrome, neurodegenerative diseases, and myotonic dystrophy)
* Epilepsy
* Vitamin B12 deficiency
Passive Leg Raising - an Important Diagnostic Manoeuvre

The aim is to describe the physiological background for PLR and the interpretation of a PLR manoeuvre.

The protocol entails the measurement of stroke volume (SV) at baseline (semirecumbent patient position), during PLR and after returning to semirecumbent position. Simultaneously blood pressure (BP), pulse rate (PR), pulse oximetric saturation (SpO2) and ECG are recorded. The procedure is performed in ten normal subjects, ten patients recruited in the cardiology outpatient department and ten critically ill patients under analgosedation in the ICU.

Analysis includes changes in measured variables and heart rate variability in the frequency domain during the three phases of the experiment.

See above

Eligibility Criteria:
Inclusion Criteria:

Consenting after written and oral information

Exclusion Criteria:

Contraindications to PLR: intracranial or abdominal hypertension
The Effect of Local Intraoperative Steroid Administration on Post-ACDF Dysphagia

Few methods were available to determine which muscle groups are associated with PD in details in previous investigations. Local steroid administration has shown some effects on PD in a large number meta-analysis. In this study, we aimed to conduct a prospective randomized-double blinded study to exam the efficacy and the safety of the local steroid administration on ACDF patients by using high resolution impedance manometry in patients receiving ACDF.

Postoperative dysphagia (PD) is the most common complication after anterior cervical discectomy and fusion (ACDF). However, few methods were available to determine which muscle groups are associated with PD in details in previous investigations. Local steroid administration has shown some effects on PD in a large number meta-analysis. In this study, we aimed to conduct a prospective randomized-double blinded study to exam the efficacy and the safety of the local steroid administration on ACDF patients, and the also apply the high resolution impedance manometry (HRIM) on patients receiving ACDF for better delineation of the swallowing function. Pressure-flow analysis (PFA), derives pharyngeal pressure flow variables obtained from HRIM were used to analyze the mechanisms of PD.

Eligibility Criteria:
Inclusion Criteria:

* patients undergoing elective anterior cervical spine surgery

Exclusion Criteria:

* patients receiving spine surgery not at the first time
* patients with head and neck cancer
* patients receiving other surgeries at head and neck region
* patients had previous swallowing difficulty history
Artificial Intelligence With Determination of Central Venous Catheter Line Associated Infection Risk

The goal of this methodological, retrospective and prospective study is to; it is a tool to develop a risk estimator tool to detect risk gaps in individuals using artificial intelligence technology that is dangerous for those with CVC in adult intensive care patients, to test risk level estimation frameworks and to evaluate outcomes in the clinic. In our study, it is also our aim to protect, to present the security measures to prevent the risk of CVC with an artificial intelligence model, in an evidence-based way.

The main question\[s\]it aims to answer are:

* Can the risk of CVC-related infection be determined in adult intensive care patients using artificial intelligence?
* To what degree of accuracy can the risk of CVC-associated infection be determined in adult intensive care patients using artificial intelligence?
* What are the nursing practices that can reduce the risk of CVC-related infections?

Methodology to develop an artificial intelligence-based CVC-associated infection risk level determination algorithm, retrospective using data from Electronic Health Records (EHR) patient data and manual patient files between January 2018 and December 2022 to create the algorithm and test the model accuracy, and the development stages of the model After the completion of the model, up-to-date data were collected for the use of the model and it was planned to be done prospectively.

The applications of artificial intelligence-based technologies in nursing are still in their infancy, and it is emphasized that nurses have limited participation in these processes. We think that our study will be supportive in determining the focal points in the clinical practice of nurses in terms of determining the risk level and will contribute to the development of patient goals. It is also important in terms of creating evidence for making the effects of nursing practices visible. In this context, the aim of our study is to develop a risk estimation tool to determine the risk levels of individuals in terms of CVC-related infection in adult intensive care patients by using artificial intelligence technology, to test the accuracy of the risk level estimation and to apply the tool to evaluate the results in the clinic. In addition, our secondary aim is to present the effects of nursing care in preventing the risk of CVC-related infection with the artificial intelligence model in an evidence-based manner.

Eligibility Criteria:
Inclusion Criteria:

* Received at least 48 hours of treatment in the GICU,
* Age ≥ 18,
* CVC inserted,
* No existing infection before hospitalization, patient data will be included in the dataset for designing and training the artificial intelligence model.

Exclusion Criteria:

* Age \<18,
* Those receiving immunosuppressive therapy,
* Those with multiple organ failure,
* Patients undergoing organ transplantation,
* Patients with a diagnosis of chronic kidney failure, will not be included in the dataset.
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.

The primary objective of the study is to collect long-term safety information on anetumab ravtansine and to enable patients, who received an anetumab ravtansine-containing treatment in any Bayer-sponsored anetumab ravtansine parent study, to continue the treatment. The secondary objective is to further investigate the efficacy of the drug.

Eligibility Criteria:
Inclusion Criteria:

* Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure.
* For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol.
* For on-treatment participants: any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption. For applicable studies: should treatment be permanently interrupted in the parent study, participants may be enrolled in the follow-up portion of the rollover study.

Exclusion Criteria:

* For on-treatment participants: a positive serum pregnancy test.
* For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol.
* Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.
Bone Height Changes In Three Implants Retained Mandibular Overdenture

this study was to compare the bone height changes around three implant telescopic, locator, and ball retained mandibular overdentures. radiographic changes in peri-implant tissue in three groups were evaluated

Twenty-four completely edentulous patients were recruited from the outpatient clinic of Removable Prosthodontics Cairo University. All patients recruited were seeking to install implants in their lower jaw, and have to meet the following inclusion criteria: age ranging from 50 to 69 years old, patients should have no contra-indication for implant installation, all patients should perform a glycosylated hemoglobin analysis and only up to 8 were included in the study. All patients had to sign an informed consent before the start of the study, and have to comply with the assigned follow-ups. Patients with any contraindications for implant placement or those who didn't comply with the follow ups were excluded from the study.

All patients included had maxillary and mandibular complete dentures fabricated following the conventional steps, after a period of 6 weeks adaptation, all patients were ready for implant installation. The lower denture was duplicated into a radiographic stent, having radio-opaque markers in the areas of implant installation. All patients had a CBCT x ray wearing the radiographic stent, to allow for proper implant planning and to visualize the height and width of the osteotomy site. The radiographic stent was then modified to a surgical stent by making a tunnel corresponding to the site of implant installation. All Patients in this study received three implants in the lower jaw at the premolar-canine area bilaterally and one implant in the midline at the central incisor area.

Eligibility Criteria:
Inclusion Criteria:

* age ranging from 50 to 69 years old, patients should have no contra-indication for implant installation, all patients should perform a glycosylated hemoglobin analysis and only up to 8 were included in the study

Exclusion Criteria:

* Patients with any contraindications for implant placement or those who didn't comply with the follow ups were excluded from the study.
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.


Eligibility Criteria:
Inclusion Criteria:

1. Male or Female age 18 or older
2. On high flow oxygen =/\> 6 liters nasal cannula (or)
3. On mechanical ventilation
4. Clinical diagnosis of COVID-19 \& positive PCR test (or)
5. Clinical diagnosis of COVID-19 \& negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan

Exclusion Criteria:

1. Known allergy to Pulmozyme
2. Less than 18 years of age
3. Grave condition with anticipated death within 48 hours; at the discretion of treating physician.
4. Enrollment in another clinical trial receiving investigatory drugs
Impaired Toilet Training, LUTS and Bowel Dysfunction in Children With DCD

This cross-sectional case-control study aimed to determine whether there is a significant difference in the prevalence of impaired toilet training, LUTS, and functional bowel problems among children diagnosed with DCD and typically developing children (TDC).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with DCD by a multidisciplinary team (DCD case group)
* Children with a typical development, grade and gender matched with the DCD case group (TDC control group).

Exclusion Criteria:

* A DCD-Q score indicative for DCD (TDC control group)
* Presence of other developmental disorders, such as ASS, ADHD or intellectual disability (TDC control group)